| Albireo Pharma is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Co.'s primary product candidate, odevixibat, is used for the indication of progressive familial intrahepatic cholestasis, a rare genetic disorder affecting young children. Co. is also developing odevixibat in biliary atresia and in Alagille syndrome. Co.'s other product candidate, elobixibat, is for the treatment of chronic constipation and for which Co. has a clinical trial as a treatment for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. We show 21 historical shares outstanding datapoints in our coverage of ALBO's shares outstanding history.|
Understanding the changing numbers of ALBO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALBO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALBO by allowing them to research ALBO shares outstanding history
as well as any other stock in our coverage universe.